DGAP-Ad-hoc: MEDIQON Group AG / Key word(s): Miscellaneous NGC Nachfolgekapital GmbH, a subsidiary of MEDIQON Group AG, entered into a transaction agreement in relation to its subsidiary vetera GmbH Today, Nordhealth A/S and NGC Nachfolgekapital GmbH, an 80% subsidiary of MEDIQON Group AG agreed that vetera GmbH, an 80% subsidiary of NGC Nachfolgekapital GmbH will become part of the Portfolio of Practice Management Software Companies of Nordhealth A/S. The consideration will be structured as a mix of cash and shares in Nordhealth A/S. Vetera is a software and service provider for veterinarians in the DACH region and was acquired by NGC Nachfolgekapital GmbH in June 2019. With the transaction, NGC Nachfolgekapital GmbH realizes a significant uplift in value compared to the original purchase price paid in 2019. The effect on the Base Value per end of 2021 as calculated by MEDIQON Group AG amounts to c. EUR 0,27 per share. Under German GAAP ("HGB"), there will be no direct impact on the financial statements of MEDIQON Group AG as the parent company. At closing, the shareholder loans granted by MEDIQON Group AG for the acquisition will be fully repaid. The transaction is expected to close in Q2 2022, subject to satisfaction of customary closing conditions.
14-March-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | MEDIQON Group AG |
Herzog-Adolph-Strasse 2 | |
61462 Königstein im Taunus | |
Germany | |
Phone: | +49 (0) 6174-9687040 |
Fax: | +49 (0) 6174-9687043 |
E-mail: | ir@mediqon-group.de |
Internet: | www.mediqon-group.de |
ISIN: | DE0006618309, DE000A254TL0 |
WKN: | 661830, A254TL |
Listed: | Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart |
EQS News ID: | 1302161 |
End of Announcement | DGAP News Service |
|
1302161 14-March-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.